1.20
0.84%
+0.01
After Hours:
1.20
Aclaris Therapeutics Inc stock is currently priced at $1.20, with a 24-hour trading volume of 442.83K.
It has seen a +0.84% increased in the last 24 hours and a +1.69% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.18 pivot point. If it approaches the $1.23 resistance level, significant changes may occur.
Previous Close:
$1.19
Open:
$1.2
24h Volume:
442.83K
Market Cap:
$85.11M
Revenue:
$31.25M
Net Income/Loss:
$-88.48M
P/E Ratio:
-0.7742
EPS:
-1.55
Net Cash Flow:
$-79.63M
1W Performance:
-3.23%
1M Performance:
+1.69%
6M Performance:
-73.80%
1Y Performance:
-86.50%
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Name
Aclaris Therapeutics Inc
Sector
Industry
Phone
484-324-7933
Address
640 Lee Road, Suite 200, Wayne, PA
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-14-22 | Initiated | Stifel | Buy |
Dec-01-22 | Initiated | Goldman | Buy |
Oct-06-22 | Initiated | BTIG Research | Buy |
Jul-23-21 | Resumed | Jefferies | Buy |
Jun-15-21 | Initiated | Piper Sandler | Overweight |
Apr-21-21 | Initiated | H.C. Wainwright | Buy |
Oct-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Sep-06-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Jun-27-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
May-06-19 | Initiated | SVB Leerink | Outperform |
Mar-28-18 | Resumed | Leerink Partners | Outperform |
Feb-09-18 | Initiated | Guggenheim | Buy |
Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
Nov-29-16 | Initiated | Leerink Partners | Outperform |
Sep-30-16 | Initiated | JMP Securities | Mkt Outperform |
Jun-10-16 | Initiated | Guggenheim | Buy |
Nov-02-15 | Initiated | Citigroup | Buy |
Nov-02-15 | Initiated | Jefferies | Buy |
View All
Aclaris Therapeutics Inc Stock (ACRS) Latest News
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Zacks Investment Research
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying
Benzinga
Aclaris (ACRS) Upgraded to Buy: Here's Why
Zacks Investment Research
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Aclaris Therapeutics Inc Stock (ACRS) Financials Data
Aclaris Therapeutics Inc (ACRS) Revenue 2024
ACRS reported a revenue (TTM) of $31.25 million for the quarter ending December 31, 2023, a +5.03% rise year-over-year.
Aclaris Therapeutics Inc (ACRS) Net Income 2024
ACRS net income (TTM) was -$88.48 million for the quarter ending December 31, 2023, a -1.81% decrease year-over-year.
Aclaris Therapeutics Inc (ACRS) Cash Flow 2024
ACRS recorded a free cash flow (TTM) of -$79.63 million for the quarter ending December 31, 2023, a -16.81% decrease year-over-year.
Aclaris Therapeutics Inc (ACRS) Earnings per Share 2024
ACRS earnings per share (TTM) was -$1.27 for the quarter ending December 31, 2023, a +4.51% growth year-over-year.
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research. Its lead product is ESKATA, a hydrogen peroxide topical solution that has completed Phase III clinical trials for the treatment of raised seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101, a hydrogen peroxide topical solution, which has completed Phase II clinical trials for the treatment of common warts. In addition, it is developing JAK inhibitors, including ATI-501, which is in Phase II clinical trials for the oral treatment of alopecia totalis and alopecia universalis; and ATI-502 that is in Phase II clinical trials for the topical treatment of patchy autoimmune dermatologic condition, vitiligo, androgenetic alopecia, and loss of eyebrow hair. Further, the company provides contract research services, such as laboratory services under contract research arrangements to pharmaceutical and biotech companies; and discovers and develops kinase inhibitors to treat inflammatory and immunological disorders and cancer. It has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Cap:
|
Volume (24h):